With over two decades’ experience in the biotechnology and pharmaceutical industry, Birgit Schultes brings deep oncology, immunology, disease biology and cell therapy expertise to Intellia. She manages a multidisciplinary team focused on ex vivo applications of CRISPR/Cas9 to generate novel cell therapies for oncology and autoimmune indications. Prior to joining Intellia, Birgit served as a senior director at Unum Therapeutics (now Cogent Biosciences, Inc.), where she directed the preclinical efforts for Unum’s universal T cell programs. Earlier in her career, Birgit held a variety of translational research roles in disease biology, oncology and immunology at Momenta Pharmaceuticals, United Therapeutics and AltaRex Corp, focusing primarily on biologics. Additionally, Birgit co-founded Advanced Immune Therapeutics, a company working on novel IgE-based cancer therapeutics.

Dr. Schultes received her M.S. in biology and Ph.D. in immunology from the University of Bonn, Germany, and completed the Advanced Management Development Program at Boston University.